Brilinta has been expensive primarily because AstraZeneca held patent protection on the drug for over a decade, blocking generic competition and allowing the company to set prices freely. A 30-day supply at retail has historically cost hundreds of dollars, while the generic alternative it replaced, clopidogrel (Plavix), costs under $10 per month in most pharmacies. The good news: generic versions of Brilinta finally started hitting the market in 2025, and prices should drop significantly as competition increases.
Patent Protection Kept Competitors Out
The core reason for Brilinta’s high price is straightforward. AstraZeneca held multiple U.S. patents on ticagrelor, the active ingredient, with expiration dates staggered across several years. The earliest key patent expired in July 2021, but additional patents extended protection much further, with one not set to expire until January 2036. These overlapping patents created a legal barrier that prevented other manufacturers from selling cheaper versions, even after the original compound patent lapsed.
While one generic manufacturer, Novadoz Pharmaceuticals, received approval for a 90 mg generic as early as April 2020, widespread generic competition didn’t materialize until spring 2025. Starting in April and May of that year, more than a dozen companies began marketing generic ticagrelor 90 mg tablets, with 60 mg versions following later in the year. This wave of competition is the single biggest factor that will bring prices down.
No Real Competitor in Its Drug Class
Brilinta occupies a unique position in heart care. It’s prescribed to reduce the risk of heart attack and stroke in people with acute coronary syndromes or a history of heart attack. The main alternative is clopidogrel, which went generic years ago and costs roughly $22 per year in Europe. Ticagrelor, by contrast, has cost closer to $788 per year in European markets and far more in the United States.
AstraZeneca justified the premium based on clinical trial results. In the landmark PLATO trial, patients taking Brilinta had a 16% lower rate of the combined outcome of cardiovascular death, heart attack, or stroke compared to those on clopidogrel (9.8% vs. 11.7%). Deaths from cardiovascular causes specifically dropped by 21% with Brilinta. Those results gave cardiologists a strong reason to prescribe it over the cheaper generic, and gave AstraZeneca leverage to charge more. When a drug can point to a measurable reduction in death rates, insurers are more willing to cover it at a higher price, and the manufacturer knows it.
U.S. Drug Pricing Works Differently
The price gap between the U.S. and other countries highlights another piece of the puzzle. In Canada, the daily cost for Brilinta 60 mg was about $2.96 Canadian, or roughly $1,080 per year, based on a negotiated price set through Ontario’s drug formulary. The U.S. has no equivalent system for negotiating or capping brand-name drug prices for most of the population. Manufacturers set their own list prices, and the actual amount patients pay depends on their insurance plan, pharmacy, and whether they use discount programs.
This lack of price regulation means U.S. patients consistently pay more for the same medication than people in Canada, the UK, or Europe, where governments negotiate directly with drug companies.
Insurance Coverage Varies Widely
How much you actually pay out of pocket for Brilinta depends heavily on your insurance. The drug has historically landed on Tier 3 or Tier 4 of most formularies, meaning higher copays or coinsurance compared to preferred generics. Medicare Part D plans have been particularly restrictive, often requiring prior authorization or step therapy (meaning you have to try clopidogrel first and document that it isn’t appropriate before the plan will cover Brilinta).
Private insurance plans have generally offered better coverage, though copays can still run $30 to $75 or more per month depending on the plan. For uninsured or underinsured patients, the full retail price has been a serious barrier to staying on the medication.
Savings Programs and How They Work
AstraZeneca offers a savings card that can reduce the cost to as low as $5 per 30-day supply for patients with commercial (private) insurance, with a maximum discount of $200 per fill. If you pay cash without insurance, the company covers up to the first $100 per month, leaving you responsible for the rest.
There’s a significant catch: patients on Medicare Part D, Medicaid, VA benefits, TriCare, or any other government-funded insurance program are not eligible for the savings card. This excludes a large portion of the people who take Brilinta, since heart disease is most common in older adults who are typically on Medicare. For those patients, the full formulary copay or coinsurance applies, with no manufacturer discount available.
Generics Are Now Available
The landscape shifted dramatically in 2025. As of mid-year, companies including Teva, Dr. Reddy’s, Apotex, Cipla, Mylan, and many others are actively marketing generic ticagrelor in the 90 mg strength, with 60 mg versions rolling out through late 2025 and into early 2026. More than 20 manufacturers have entered the market or are in the process of launching.
When this many generic competitors enter at once, prices typically drop by 80% or more within the first year. If you’re currently paying a high copay or cash price for brand-name Brilinta, ask your pharmacist whether a generic version is available at your pharmacy. Your prescriber doesn’t necessarily need to write a new prescription, since most states allow automatic substitution of an FDA-approved generic unless the doctor specifically requests the brand.
For patients who have been stretching doses or skipping fills because of cost, the arrival of generic ticagrelor is a meaningful change. The medication works best when taken consistently, and the price drop removes one of the biggest obstacles to staying on it.